What Did FDA Approve About Mimrylo (Rusfertide)?
The concise answer
Yes. On August 28, 2026, the U.S. Food and Drug Administration approved Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera. The FDA describes it as the first approved polycythemia vera treatment that mimics hepcidin, a hormone involved in regulating iron. The approval was supported by the 293-participant phase 3 VERIFY trial.
The approval is specific: it applies to the FDA-approved branded drug, its labeled indication and the regulated product reviewed by the agency. It does not mean that every item described online as “rusfertide,” “PTG-300” or a “research peptide” is FDA approved, equivalent to Mimrylo or suitable for human use.
Status note: The FDA approval, trial registry and sources in this article were checked on August 31, 2026. This article explains regulatory and research evidence; it does not provide treatment or dosing advice.
What exactly did the FDA approve?
The FDA announced that it approved Mimrylo, whose active ingredient is rusfertide, for erythrocytosis in adults with polycythemia vera. The FDA-approved prescribing information uses that exact indication, and the agency’s 2026 novel-drug approval list records the same August 28 approval.
Mimrylo received priority review, and the approval was granted to Takeda Pharmaceuticals America, Inc. “Priority review” describes the FDA’s review timeline; it is not a claim that the drug works for uses outside its approved labeling.
The first-in-class point also needs precise wording. Mimrylo is not the first treatment ever used for polycythemia vera. It is the first FDA-approved treatment for polycythemia vera that mimics hepcidin, according to the agency.
What is polycythemia vera, and why does hematocrit matter?
Polycythemia vera is a rare blood disorder in which the body produces too many red blood cells. The FDA explains that the excess cells can thicken the blood and increase the risk of cardiovascular problems, including blood clots, stroke and heart attack.
One management goal is to keep hematocrit—the proportion of blood made up of red blood cells—below 45%. Phlebotomy, a procedure that removes blood from a vein, is commonly used to lower red-blood-cell levels. Some patients continue to require frequent phlebotomies despite ongoing therapy, which is the population studied in the pivotal VERIFY trial.
This background explains the trial’s focus. The central question was not whether rusfertide could treat every feature of polycythemia vera. It was whether adding rusfertide to existing care could improve hematocrit control and reduce the need for phlebotomy in a defined group of adults.
How does rusfertide mimic hepcidin?
Hepcidin is a hormone that helps regulate iron availability. Red-blood-cell production requires iron. The approved label describes rusfertide as a synthetic cyclic peptide that mimics endogenous hepcidin and blocks the iron transporter ferroportin. This reduces the iron available for red-blood-cell production and lowers hematocrit.
The VERIFY registry record identifies the compound as rusfertide, previously known as PTG-300. The mechanism is scientifically notable because it targets iron regulation rather than simply removing blood after excess red blood cells have already accumulated.
A plausible mechanism is not sufficient by itself for approval. The regulatory decision also required clinical evidence about efficacy and safety in the intended population.
What did the phase 3 VERIFY trial test?
VERIFY, ClinicalTrials.gov identifier NCT05210790, was a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. The FDA summarizes the pivotal comparison as follows:
- 293 adults with polycythemia vera were enrolled.
- Participants required frequent phlebotomies despite ongoing standard-of-care therapy.
- Participants were randomized 1:1 to Mimrylo or placebo for 32 weeks, added to their existing care.
- The study treatment was administered subcutaneously once weekly and titrated under the trial protocol to maintain hematocrit below 45%.
- The efficacy measure was the proportion of participants who did not meet the criteria for phlebotomy during weeks 20 through 32.
The label defines phlebotomy eligibility precisely: either a confirmed hematocrit of at least 45% that was at least three absolute percentage points above baseline, or a hematocrit of at least 48%. That protocol definition is important because “no phlebotomy eligibility” is not the same as a general claim of cure or permanent independence from phlebotomy.
The study’s design matters. Randomization and blinding reduce important sources of bias, while the placebo group shows what happened under the comparator condition during the same period. The result still applies to the trial’s enrolled population, protocol and endpoint—not automatically to every patient or every cause of elevated hematocrit.
What did VERIFY show?
The FDA-approved label reports several group-level outcomes:
- 76.9% of participants receiving Mimrylo met the no-phlebotomy response measure, compared with 32.9% receiving placebo.
- The mean number of phlebotomies from baseline through week 32 was 0.53 with Mimrylo and 1.82 with placebo.
- 62.6% of the Mimrylo group maintained hematocrit below 45% from weeks 0 through 32, compared with 14.4% of the placebo group.
- Mean change in the PROMIS fatigue score at week 32 was −1.79 with Mimrylo and +0.19 with placebo; lower scores represent less fatigue.
That is a substantial trial difference, but the wording should remain tied to the endpoint. It does not mean that Mimrylo permanently eliminated phlebotomy for 76.9% of all people with polycythemia vera. It means that this proportion of the Mimrylo group met the study’s response definition during the specified trial period.
The placebo result is useful context. Nearly one-third of participants in the placebo group also met the response measure, which is one reason the controlled comparison matters more than quoting the Mimrylo percentage alone.
The approval-supporting endpoints concerned phlebotomy eligibility, number of phlebotomies, hematocrit control and fatigue. They should not be expanded into claims that VERIFY demonstrated fewer strokes, fewer blood clots, slower disease progression or improved survival.
As of the source review for this article, the public phase 3 evidence included the FDA-approved label and a 2025 Journal of Clinical Oncology meeting abstract. We did not identify a full-length, peer-reviewed VERIFY phase 3 paper. The peer-reviewed 2024 New England Journal of Medicine paper reports the earlier phase 2 REVIVE study, not VERIFY.
What did the FDA say about adverse reactions?
In the randomized 32-week period, the approved label reports injection-site reactions in 56% of Mimrylo-treated participants and anemia in 16%. The label also contains warnings and precautions concerning new or worsening thrombocytosis, injection-site reactions and embryo-fetal toxicity.
Those points are a summary, not a complete safety profile. Readers should use the current full prescribing information, rather than an article or social-media post, for complete safety and prescribing information.
No article can determine whether a prescription drug is appropriate for a particular person. Patients and clinicians should use the FDA-approved prescribing information and individual medical assessment, not a research-library summary, when making treatment decisions.
Is the VERIFY trial still ongoing after FDA approval?
The ClinicalTrials.gov record lists VERIFY as active, not recruiting and gives an estimated study-completion date in June 2027. The registry describes an open-label extension and later safety follow-up after the randomized 32-week portion.
That does not contradict the approval. Regulators can act on a defined evidence package while longer follow-up or extension phases continue. The accurate description is that FDA approved Mimrylo based on the reviewed evidence, while the registered study record still includes ongoing follow-up.
It would be inaccurate to turn the active registry status into either of two extremes: “the study is unfinished, so the approval is not real,” or “the drug is approved, so no additional evidence is being collected.” Both approval and continued follow-up can be true at the same time.
What does the Mimrylo approval not mean?
The approval does not establish that:
- every product or vial labeled rusfertide is Mimrylo;
- a research material is equivalent to the FDA-approved drug;
- rusfertide is approved for other conditions or for any person with an elevated hematocrit;
- the VERIFY percentages predict an individual outcome;
- no participant will ever need phlebotomy again;
- continued safety monitoring or research is unnecessary; or
- another hepcidin-mimetic candidate shares Mimrylo’s approval.
FDA explains that drug approval reviews product-specific information and whether manufacturing can reliably produce the expected identity, strength, quality and purity. Approval therefore attaches to the reviewed finished drug product, its manufacturing controls, labeling, evidence package and conditions of use. A compound name by itself does not transfer that approval to unrelated material. For broader context, see FDA’s concerns about unapproved drugs and JD BioWorks’ guide to what research peptides are.
How is this different from a positive phase 2 or phase 3 headline?
A positive trial result, a peer-reviewed publication, a recruiting study and FDA approval are different milestones.
For example, JD BioWorks’ zenagamtide phase 2 review describes completed human research but explicitly notes that the compound remained investigational when checked. Our avexitide phase 3 review covers sponsor-reported topline findings while separating those findings from peer review and regulatory approval.
Mimrylo has now crossed the separate regulatory milestone: the FDA lists the drug and its approved indication. That status should be reported precisely, without extending it to other products or uses.
Frequently asked questions
Is Mimrylo FDA approved?
Yes. The FDA approved Mimrylo (rusfertide) on August 28, 2026, for the treatment of erythrocytosis in adults with polycythemia vera.
Is rusfertide a peptide?
Yes. The FDA-approved prescribing information describes rusfertide as a synthetic cyclic peptide and a hepcidin mimetic. Mimrylo is the approved branded drug containing rusfertide.
Are rusfertide and PTG-300 the same compound?
PTG-300 was a development identifier for rusfertide. The official VERIFY title lists “rusfertide (PTG-300).” That naming history does not make unrelated material equivalent to the approved product.
Did Mimrylo eliminate the need for phlebotomy?
The pivotal trial found that 76.9% of the Mimrylo group met the no-phlebotomy response measure during the defined assessment period, compared with 32.9% on placebo. That is not a guarantee of permanent phlebotomy independence for every patient.
Does FDA approval mean the clinical trial is completely finished?
No. ClinicalTrials.gov lists VERIFY as active, not recruiting, with extension and follow-up activity. FDA approval and continued evidence collection are not mutually exclusive.
Does this approval apply to research-use rusfertide sold online?
No. The approval applies to Mimrylo under its FDA-reviewed labeling and manufacturing framework. It does not approve independently supplied research materials, establish equivalence or authorize human use of products labeled for research only. JD BioWorks’ Research Use Disclaimer explains the separate restrictions that apply to laboratory research materials.
The bottom line
Mimrylo is a genuine first-in-class FDA approval: rusfertide is now approved for erythrocytosis in adults with polycythemia vera, and the drug is the first approved treatment for the disease that mimics hepcidin. In the randomized phase 3 VERIFY trial, the Mimrylo group was more likely than the placebo group to meet a defined no-phlebotomy response measure.
The responsible takeaway is specific, not sweeping. The approval concerns the regulated Mimrylo product and its labeled indication. It does not confer approval on unrelated rusfertide materials, erase the limits of the trial endpoint or replace individualized medical decision-making.
For more source-linked coverage of clinical and regulatory milestones, browse the JD BioWorks Research Library and review our Scientific Sourcing and Editorial Standards.
Primary sources
- U.S. Food and Drug Administration. FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder. August 28, 2026.
- U.S. Food and Drug Administration. Novel Drug Approvals for 2026.
- Mimrylo FDA-approved prescribing information. Revised August 2026.
- ClinicalTrials.gov. NCT05210790: A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera.
- Kuykendall AT, et al. Results from VERIFY, a phase 3, double-blind, placebo-controlled study of rusfertide for treatment of polycythemia vera. Journal of Clinical Oncology. 2025;43(suppl 17):LBA3. Meeting abstract.
- Kremyanskaya M, et al. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. New England Journal of Medicine. 2024;390:723–735. Phase 2 REVIVE study.
- U.S. Food and Drug Administration. FDA’s Concerns About Unapproved Drugs.
Medical and research-use disclaimer: This article provides general educational information about regulatory status and published clinical research. It is not medical advice, diagnosis, treatment guidance or a recommendation to use rusfertide. Prescription-drug decisions belong with licensed clinicians using current FDA-approved labeling. JD BioWorks materials are intended for qualified laboratory research only and are not for human or veterinary use. A research-use label, compound name or analytical result does not establish equivalence to Mimrylo, FDA approval, safety, efficacy or clinical suitability.